ongericimab   Click here for help

GtoPdb Ligand ID: 13787

Synonyms: JS-002 | JS002 | Junshida®
Approved drug
ongericimab is an approved drug
Compound class: Antibody
Comment: Ongericimab (JS002) is a subcutaneous humanized anti-proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibody [1]. It blocks binding between circulating PCSK9 and the LDL receptor on hepatocytes. This reduces LDL receptor degradation, thus increasing the number of LDL receptors on cells, and effectively increasing hepatic removal LDL cholesterol (LDL-C) from the circulation. Ongericimab was developed for patients at high risk for cardiovascular disease, as an add-on treatment when standard lipid-lowering therapy fails to achieve LDL-C target level.
Classification Click here for help
Compound class Antibody
Approved drug? Yes. China NMPA (2024)
International Nonproprietary Names Click here for help
INN number INN
11188 ongericimab
Synonyms Click here for help
JS-002 | JS002 | Junshida®
Database Links Click here for help
Specialist databases
IMGT/mAb-DB 1021
Other databases
GtoPdb PubChem SID 507750420
Search PubMed clinical trials ongericimab
Search PubMed titles ongericimab
Search PubMed titles/abstracts ongericimab